Clinical Trial Update: A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating subcutaneous tocilizumab in participants with polyarticular-course juvenile idiopathic arthritis has completed, with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Juvenile Idiopathic Arthritis | Phase 1 | Status: COMPLETED | Results posted: 2017-03-16